Advertisement
BME vs XLV
Which ETF would AI Choose? BlackRock Health Sciences Trust (BME) vs. Health Care Select Sector SPDR Fund (XLV)
Key Takeaways
- BME is an actively managed closed-end fund (CEF) focused on health sciences, while XLV is a passively managed exchange-traded fund (ETF) that replicates the Health Care Select Sector Index.
- Both portfolios are essentially 100% healthcare, but BME holds roughly 161 positions versus about 62–64 large-cap names in XLV.
- The cost gap is significant: XLV charges a 0.08% net expense ratio, compared with roughly 1.10%–1.13% for BME.
- BME emphasizes income with a distribution rate near 8% and can trade at premiums or discounts to net asset value (NAV); XLV offers a roughly 1.5% yield and trades close to NAV.
- Scale and liquidity favor XLV (about $44 billion in assets) over BME (about $563 million).
- Tickeron AI Verdict: XLV is favored for most investors on cost efficiency, liquidity, and structural simplicity.
Introduction
Investors seeking exposure to the healthcare sector face a meaningful structural choice. BME, the BlackRock Health Sciences Trust, is an actively managed closed-end fund (CEF) that pursues total return and income across the health sciences universe. XLV, the Health Care Select Sector SPDR Fund, is a low-cost, index-based ETF tracking the healthcare constituents of the S&P 500 (Standard & Poor's 500). They do not compete directly on structure, but they offer alternative routes to the same sector, making this an instructive ETF comparison for investors weighing active income generation against passive, large-cap beta.
BlackRock Health Sciences Trust (BME) Overview
Launched in March 2005, BME is a perpetual closed-end fund (CEF) actively managed by BlackRock. Its objective is total return and income, primarily through long-term capital appreciation, and it invests at least 80% of assets in equity securities and equity derivatives tied to the health sciences industry. The portfolio holds roughly 161 positions, including some non-U.S. names and smaller-capitalization companies beyond the large-cap index universe.
Top holdings include LLY (Eli Lilly) near 11%, JNJ (Johnson & Johnson) near 8.5%, ABBV (AbbVie) near 4%, ABT (Abbott Laboratories) near 4%, MRK (Merck), UNH (UnitedHealth Group), GILD (Gilead Sciences), and AMGN (Amgen). The fund is essentially 100% healthcare, carries a total expense ratio near 1.10%–1.13%, and distinguishes itself through active security selection, an income-oriented distribution policy, and the ability to use options strategies. As a CEF, BME trades on an exchange at a price that can diverge from its NAV, introducing premium/discount risk.
Health Care Select Sector SPDR Fund (XLV) Overview
XLV launched in December 1998 and is a passively managed ETF that seeks to track the Health Care Select Sector Index, comprising healthcare companies drawn from the S&P 500 and weighted by market capitalization. It employs a replication strategy, holding roughly 62–64 large-cap names across pharmaceuticals, biotechnology, health care equipment and supplies, providers and services, and life sciences tools.
Top holdings are LLY (Eli Lilly) near 15%, JNJ (Johnson & Johnson) near 10%, ABBV (AbbVie) near 7.7%, MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), AMGN (Amgen), GILD (Gilead Sciences), ABT (Abbott Laboratories), and PFE (Pfizer). The fund charges a 0.08% net expense ratio, holds roughly $44 billion in assets under management (AUM), and is among the most liquid healthcare vehicles available, with minimal tracking error and low turnover.
Industry and Thematic Backdrop
Both funds are shaped by a healthcare sector defined by innovation and policy. Weight-loss and metabolic (GLP-1) treatments have concentrated investor attention on names like Eli Lilly, while aging demographics and strong cash flows support the defensive profile of large-cap pharmaceuticals and medical device makers. At the same time, the sector faces regulatory and pricing pressure, patent cliffs, and ongoing debate over drug pricing and Medicare policy. Interest-rate expectations also matter, since healthcare is often treated as a long-duration, bond-proxy equity sector whose valuations respond to shifts in real yields. These forces lift or pressure both funds, though BME's active mandate allows it to adjust sector and company exposure more flexibly than XLV's rules-based, market-cap weighting.
Performance and Positioning Comparison
Across recent market cycles, both funds have benefited from the leadership of a small group of large-cap pharmaceutical and biotech names, particularly Eli Lilly. XLV's market-cap construction concentrates returns in those leaders and gives the fund a relatively low beta (roughly 0.6), producing defensive relative positioning. BME has also leaned on similar mega-cap names but pairs them with active selection across mid- and small-cap healthcare, a higher expense burden, and the return variability created by premium/discount movements in a closed-end structure. BME has historically carried somewhat higher volatility than XLV, reflecting its more concentrated active bets and its CEF wrapper. In broad terms, XLV offers a smoother, lower-cost, large-cap profile, while BME trades cost efficiency and liquidity for potential alpha (excess return) and a meaningfully higher distribution rate.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors comparing vehicles like BME and XLV, the AI Screener offers a data-driven starting point for refining a healthcare watchlist.
Tickeron AI Verdict
Based on observable structural factors, Tickeron's AI would currently favor XLV over BME. XLV combines a dramatically lower expense ratio (0.08% versus roughly 1.10%), superior liquidity, passive transparency, and lower structural volatility, attributes that tend to improve long-term risk-adjusted outcomes for most investors. BME's active management and high distribution rate may appeal to income-oriented investors, but those benefits come with higher fees and premium/discount uncertainty around its NAV. On cost efficiency, diversification quality, and relative positioning, the probabilistic edge currently lies with XLV.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BME is a Buy and XLV is a Hold.
BME in upward trend: price rose above 50-day moving average on October 19, 2026
BME moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on BME as a result. In 70 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for BME just turned positive on October 14, 2026. Looking at past instances where BME's MACD turned positive, the stock continued to rise in 47 of 53 cases over the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for BME crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +0.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where BME advanced for three days, in 271 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 210 of 250 cases where BME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for BME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 17 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
BME broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
XLV in upward trend: price rose above 50-day moving average on October 09, 2026
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 77 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 263 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 230 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 30 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XLV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| BME | XLV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| Advances ODDS (%) | 5 days ago 79% | 8 days ago 81% |
| Declines ODDS (%) | 15 days ago 77% | 4 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 85% |
Advertisement
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.
| Ticker / NAME | Correlation To XLV | 1D Price Change % | ||
|---|---|---|---|---|
| XLV | 100% | -2.50% | ||
| LLY - XLV | 75% Closely correlated | -3.76% | ||
| AMGN - XLV | 70% Closely correlated | -3.80% | ||
| MRK - XLV | 65% Loosely correlated | -2.27% | ||
| JNJ - XLV | 63% Loosely correlated | -1.45% | ||
| ABBV - XLV | 63% Loosely correlated | -2.24% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DCMT | 36.21 | 0.16 | +0.43% |
| DoubleLine Commodity Strategy ETF (DCMT) | |||
| ADVE | 44.31 | N/A | N/A |
| Matthews Asia Dividend Active ETF (ADVE) | |||
| UFEB | 38.98 | -0.85 | -2.13% |
| Innovator U.S. Equity Ultra Buffer ETF - February (UFEB) | |||
| FMAT | 58.46 | -1.77 | -2.94% |
| Fidelity MSCI Materials Index ETF (FMAT) | |||
| VCR | 391.82 | -16.41 | -4.02% |
| Vanguard Consumer Discretionary ETF (VCR) | |||